KFO 129:  Mechanisms for Development of Resistance and Optimisation of Antiviral Strategies of Hepatitis C Virus Infection Comprising Integrative Biomathematical and Bioinformatical Models

• Subject Area: Medicine
• Term: from 2005 to 2010
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 5397647

• Final Report Year: 2013

No abstract available

Publications

• Clinical significance of in vitro replication-enhancing mutations of the hepatitis C virus (HCV) replicon in patients with chronic HCV infection. Journal of Infectious Diseases, Vol. 192. 2005, Issue 10, pp. 1710–1719.
  C. Sarrazin, U. Mihm, E. Herrmann, C. Welsch, M. Albrecht, et al., T. Lengauer, S. Zeuzem
  
• Amino acid variations in hepatitis C virus p7 and sensitivity to antiviral combination therapy with amantadine in chronic hepatitis C. Antiviral Therapy, Vol. 11. 2006, Issue 4, pp. 507-519.
  U. Mihm, N. Grigorian, C. Welsch, E. Herrmann, B. Kronenberger, et al., W.P. Hofmann, M. Albrecht, T. Lengauer, S. Zeuzem, C. Sarrazin
  
• Dynamics of apoptotic activity during antiviral treatment of patients with chronic hepatitis C. Antiviral Therapy, Vol. 12. 2007, Issue 5, pp. 779-787.
  B. Kronenberger, S. Zeuzem, C. Sarrazin, U. Mihm, W.P. Hofmann, E. Herrmann et al.
  
• Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy. Gastroenterology, Vol. 132. 2007, Issue 3, pp. 921-930.
  W.P. Hofmann, A. Polta., E. Herrmann, U. Mihm, B. Kronenberger, et al., S. Zeuzem, C. Sarrazin
  
• Somatic hypermutation and mRNA expression levels of the BCL-6 gene in patients with hepatitis C virus-associated lymphoproliferative diseases. Journal of Viral Hepatitis, Vol. 14. 2007, Issue 7, pp. 484-491.
  W.P. Hofmann, B. Fernandez, E. Herrmann, C. Welsch, U. Mihm, B. Kronenberger, et al., S. Zeuzem, C. Sarrazin
  
• Structural and functional comparison of the non-structural protein 4B in flaviviridae. Journal of Molecular Graphics and Modelling, Vol. 26. 2007, Issue 2, pp. 546-557.
  C. Welsch, M. Albrecht, E. Herrmann, M.W. Welker, C. Sarrazin, A. Scheidig, T. Lengauer, S. Zeuzem, et al.
  
• Clinical relevance of the 2'-5'-oligoadenylate synthetase/RNase L system for treatment response in chronic hepatitis C. Journal of Hepatology, Vol. 50. 2009, Issue 1, pp. 49-58.
  U. Mihm, et al., C. Welsch, E. Herrmann, W.P. Hofmann, T. Lengauer, S. Zeuzem, C. Sarrazin, et al.
  
• Comparison of Envelope 2 CD81 binding regions in PBMC-derived versus serum-derived hepatitis C virus isolates: higher conservation of CD81 region 2 in PBMC isolates. Journal of Viral Hepatitis, Vol. 18. 2011, Issue 3, pp. 181-192.
  M.W. Welker, C. Welsch, W.P. Hofmann, E. Herrmann, R.W. Hartmann, S. Zeuzem, C. Sarrazin, B. Kronenberger, et al.
  
• Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir. Antiviral Therapy, Vol. 16. 2011, Issue 5, pp. 695-704.
  W.P. Hofmann, T.L. Chung, C. Osbahr, S. Susser, U. Mihm, C. Welsch, J. Lötsch, C. Sarrazin, S. Zeuzem, E. Herrmann, et al.
  
• Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C. Pharmacogenetics and Genomics, Vol. 21. 2011, Issue 5, pp. 289-296.
  A. Doehring, W.P. Hofmann, C. Schlecker, S. Zeuzem, C. Sarrazin, E. Herrmann, G. Geißlinger, J. Lötsch, et al.